louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04525625: Risk Factors for Acute Kidney Injury in Critically Ill Patients With Acute-on-Chronic Liver Failure
Official title: Risk Factors for Acute Kidney Injury in Critically Ill Patients With Acute-on-Chronic Liver Failure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Kidney Injury
Acute-On-Chronic Liver Failure
Lead sponsor: Institutul Clinic Fundeni
Sponsor class: OTHER
First posted: 2020-08-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients admitted to a general ICU for ACLF who fall into the inclusion and exclusion criteria. Standard treatment will be applied to all patients and no supplemental intervention is required for the present study.

Brief summary: Acute kidney injury (AKI) is one of the most important factors associated with increased mortality in patients with acute-on-chronic liver failure (AoCLF). Early identification and treatment of this subgroup of patients may improve survival and decrease ICU length of stay. As kidney ischemia is one of the main mechanisms responsible for AKI in AoCLF, an increase in urinary to arterial partial pressure of oxygen may help in the early diagnosis of renal failure. For this arterial and urinary oxygen pressure will be measured at ICU admission, on day 1 and day 3 of ICU stay. Diagnosis of AKI within the first 28 days after ICU admission will be recorded


Eligibility criteria: Inclusion Criteria:

- patients admitted to the ICU for acute-on-chronic liver failure

Exclusion Criteria:

* pre-existing renal disease
* urine output\<200 mL/day
* death within the first 24 hours after ICU admission
* emergency liver transplantation within the follow-up period (28 days)

Primary outcomes:
measure: AKI
timeFrame: 28 days after ICU admission
Secondary outcomes:
measure: arterial to urinary oxygen gradient
timeFrame: ICU admission, ICU day 1 and ICU dy 3
measure: mortality
timeFrame: 28-days
Other outcomes:
Locations:
city: Bucharest
country: Romania
facility: Popescu Mihai
Study officials:
affiliation: Fundeni Clinical Institute
name: Dana Tomescu, Prof
role: STUDY_CHAIR
References:
Clinical trial NCT04877925: Coaxial Drainage Versus Standard Chest Tube After Pulmonary Lobectomy
Official title: Coaxial Drainage Versus Standard Chest Tube After Pulmonary Lobectomy: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Cancer
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2021-05-07
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objectives: Chest tubes are routinely inserted after thoracic surgery procedures in different size and numbers. The aim of this study is to assess the efficacy of Smart Drain Coaxial drainage compared with two standard chest tubes in patients undergoing thoracotomy for pulmonary lobectomy. 98 patients (57 males and 41 females, mean age 68.3±7.4 years) with lung cancer undergoing open pulmonary lobectomy were randomized in two groups: 50 received one upper 28-Fr and one lower 32-Fr standard chest tube (ST group) and 48 received one 28-Fr Smart Drain Coaxial tube (CT group). Hospitalization data, quantity of fluid output, air leaks, radiograph findings, pain control and costs were assessed.


Eligibility criteria: Inclusion Criteria:

* age more than 18 years
* patients scheduled for pulmonary lobectomy

Exclusion Criteria:

* middle lobectomy,
* extended resections, minimally invasive lobectomies,
* previous ipsilateral thoracic surgery,
* induction chemo and/or radiotherapy
* patients who did not give consent to participate.

Primary outcomes:
measure: Daily fluid drainage (mL)
timeFrame: 1 postoperative day
measure: Presence of postoperative pneumothorax
timeFrame: 1 postoperative day
Secondary outcomes:
measure: presence of pneumothorax after tubes removal
timeFrame: within 24 hours after tubes removal
measure: evaluation of pain measured by Visual Analogue Scale
timeFrame: 1 postoperative day
measure: Analysis of costs (in euros)
timeFrame: until discharge, an average of 6 days
measure: Postoperative hospitalization (in days)
timeFrame: until discharge, an average of 6 days
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Sapienza University of Rome
Study officials:
References:
citation: Guerrera F, Filosso PL, Pompili C, Olivetti S, Roffinella M, Imperatori A, Brunelli A. Application of the coaxial smart drain in patients with a large air leak following anatomic lung resection: a prospective multicenter phase II analysis of efficacy and safety. J Vis Surg. 2018 Jan 29;4:26. doi: 10.21037/jovs.2018.01.07. eCollection 2018.
citation: Rena O, Parini S, Papalia E, Massera F, Turello D, Baietto G, Casadio C. The Redax(R) Coaxial Drain in pulmonary lobectomy: a study of efficacy. J Thorac Dis. 2017 Sep;9(9):3215-3221. doi: 10.21037/jtd.2017.08.110.
Clinical trial NCT00589225: Primary Hyperoxaluria Mutation Genotyping
Official title: Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Hyperoxaluria
Keywords: PH
PH type I
Primary Hyperoxaluria
Hyperoxaluria
Primary Oxalosis
PH type II
PH type III
Genetic testing for PH
Genetic testing for Primary Hyperoxaluria
Hereditary study for PH
Hereditary study for Primary Hyperoxaluria
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
name: Oxalosis and Hyperoxaluria Foundation (OHF)
First posted: 2008-01-09
Enrollment: 902
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Patients with clinical findings suggestive of primary hyperoxaluria
* Family members of patiente with clinical findings suggestive of primary hyperoxaluria

Brief summary: This study will help us determine whether certain genetic mutations, more than others, are a cause of more severe disease in Primary Hyperoxaluria.

Detailed description: During your study visit, we will draw one tube, about two teaspoonfuls (1 to 1 ½ teaspoons for children), of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing. We will use the isolated DNA to try to identify the gene that is defective in Primary Hyperoxaluria by comparing it with the structure of genes in normal individuals, patients with Primary Hyperoxaluria, and family members of Primary Hyperoxaluria patients. In family members of primary hyperoxaluria patients, a 24 hour urine test may also be collected.

Eligibility criteria: Inclusion Criteria:

* You have been diagnosed, or you are in the process of being diagnosed Primary Hyperoxaluria
* You have a family member diagnosed with Primary Hyperoxaluria

Primary outcomes:
measure: To determine whether certain genetic mutations, more than others, are a cause of more severe disease in Primary Hyperoxaluria
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Dawn Milliner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07013825: Prediction of Emergency Department Admission Volume
Official title: Prediction of Emergency Department Admission Volume
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emergency
Lead sponsor: Centre Hospitalier de Saint-Denis
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study participants will be selected from a population of patients who meet specific inclusion and exclusion criteria. Specifically, the population will consist of individuals who:

Are adult patients (i.e., not minors),

Have not refused to be included in the study, as indicated in their medical records,

Have not objected to the use of their medical data or explicitly refused to participate,

Have had at least one consultation at the emergency department in the year prior to the study period.

Thus, the study population will include adult patients with documented emergency department visits in the past year, who have not opted out of data use and have no recorded refusal to participate.

Brief summary: Retrospective cohort. Schedule emergency service overload periods on different terms, by hour or time slot over several days.


Eligibility criteria: Minor patients Refusal of inclusion in a study explicitly stated in the medical record Objection to the use of data or refusal to participate No consultation at the emergency department in the year prior to the study

Primary outcomes:
measure: Rate of admissions to emergency rooms
timeFrame: 01/01/2022 - 31/12/2022
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Denis
country: France
facility: France
Study officials:
References:
Clinical trial NCT00205322: Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
Official title: A Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Colorectal Cancer
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications.


Eligibility criteria: Inclusion Criteria:

* no prior treatment for metastatic disease
* PS 0-2
* measurable disease

Exclusion Criteria:

* neuropathy \> or equal to grade 2
* concomitant radiation therapy or other systemic cancer therapies
* brain mets

Primary outcomes:
measure: Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients
timeFrame: Bi-monthly collection of information regarding tumor progression and overall survival.
Secondary outcomes:
measure: Is the oral drug an advantage in this patient population
timeFrame: Bi-monthly collection of information regarding tumor progression and overall survival
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Daniel Mulkerin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00392522: 50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy
Official title: 50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy : Randomized, Double Blind, Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Fiberoptic Bronchoscopy
Keywords: Anxiety
Cough
Number of general anaesthesias (due to procedure failure)
Patients satisfaction
Chest physician satisfaction
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2006-10-26
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fiberoptic bronchoscopy may generate pain, anxiety or cough and dyspnea. It may then induce discomfort and then run down its yield. Systematic local anaesthesia does not always suffice and FOB may be conducted under general anaesthesia. Premixed nitrous oxide and oxygen (MEOPA) could be efficient to avoid general anesthesia risks and to reduce organizational costs. Nitrous oxide induces anaelgesia and anxiolysis when administered in oxygen at a 50% concentration.

MEOPA is being delivered in France for every short painful medical in-patients procedure since 2001. At a concentration of 50% in oxygen, and delivered through a facial mask, it produces a conscious sedation useful during endoscopy. MEOPA safety is due to its short term effect, which ends 5 minutes after cessation of inhalation. It therefore allows ambulatory medicine.

Two randomized double blind controlled studies were driven in fiberoptic bronchoscopy (Fauroux 2004, Atassi 2005) and showed its efficacy on pain control and sedation.

We will perform our Study to estimate MEOPA efficacy in term of pain control (Visual Analogic Scale (VAS)), anxiety control (COVI Scale), cough and number of general anaesthesias, comparing FOB under MEOPA and Oxygen (double blind, randomized, placebo-controlled study.


Eligibility criteria: Inclusion Criteria:

* Man or woman over 18 who should undergo a fiberoptic bronchoscopy (inpatient and outpatient)

Exclusion Criteria:

* Child under 18
* Pneumothorax
* ocular surgery in the previous 3 months,
* intracranial overpressure
* lucidity impairment
* emphysema bullae
* face trauma
* angina pectoris
* hemodynamic instability
* acute respiratory distress
* hypercapnia \> 45 mm Hg
* pregnancy
* lidocaine allergia
* lack of approuval from the patient to perform the study will of the patient to undergo FOB with premixed nitrous oxide-oxygen

Primary outcomes:
measure: Efficacy in term of pain control Visual Analogic Scale
Secondary outcomes:
measure: anxiety control (COVI Scale)
measure: cough
measure: number of general anaesthesias
Other outcomes:
Locations:
city: Lyon
country: France
facility: Corinne Depagne
Study officials:
affiliation: Hospices Civils de Lyon
name: Corinne DEPAGNE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03502122: Design and Verification of Individualized Smart Assistive Devices for Stroke Rehabilitation
Official title: Design and Verification of Individualized Smart Assistive Devices for Stroke Rehabilitation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: stroke
rehabilitation
Lead sponsor: National Central University, Taiwan
Sponsor class: OTHER
First posted: 2018-04-18
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to design and verify a multi-mode smart assistive device system for Stroke Rehabilitation by using EEG, fMRI, IMU and questioners


Eligibility criteria: Inclusion Criteria:

* the first time hemiparetic stroke;
* diagnosis confirmed by a physician on the basis of the findings of neurological examinations and brain imaging (magnetic resonance imaging or computed tomography scan);
* aged between 20 and 85 years;
* Brunnstrom's stage II to V over the proximal and distal part of the upper extremity on the affected side;
* no cognitive dysfunction, measured by the Mini-Mental State Exam (≧24; suggested by 36 with respect to age and educational level)
* willing/able to participate and having signed an informed consent form.

Exclusion Criteria:

* unstable vital sign
* irreversible contracture over any of the joints of the affected upper extremity
* history of surgery, fracture, arthritis, pain, or any other complications that might influence the recovery of upper extremity function like aphasia, apraxia and neglect;
* having spasticity, as measured using the Modified Ashworth scale (score \> 2);
* poststroke seizure;
* heart attack within 3 months poststroke; cortical lesions in any of the five core motor areas of interest, including the bilateral M1, the bilateral PM, and the SMA.

Primary outcomes:
measure: Change in FUGL- MEYER ASSESSMENT OF PHYSICAL PERFORMANCE (FMA)
timeFrame: pre, post (after 24 hrs of intervention) and follow-up (one month after finishing intervention )
Secondary outcomes:
measure: change in upper extremity performance evaluation test for the elderly (TEMPA)
timeFrame: pre, post (after 24 hrs of intervention) and follow-up (one month after finishing intervention )
measure: change in Brunnstrom stage
timeFrame: pre, post (after 24 hrs of intervention) and follow-up (one month after finishing intervention )
measure: change in Wolf motor function
timeFrame: pre, post (after 24 hrs of intervention) and follow-up (one month after finishing intervention )
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00249522: Vouchers vs. Prizes for Methadone Patients - 1
Official title: Vouchers vs. Prizes for Methadone Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Abuse
Keywords: contingency management
substance abuse treatment
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: UConn Health
First posted: 2005-11-07
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare voucher-based contingency management (CM) procedures to a lower-cost CM system that provides opportunities to win prizes. Cocaine-dependent outpatients are randomly assigned to (a) standard treatment, (b) standard treatment plus voucher CM for abstinence, defined by negative breath and urinalysis test results, or (c) standard treatment plus prize CM for abstinence, defined by negative breath and urinalysis test results. Urine and breath samples are collected 3x/week during Weeks 1-3, 2x/week during Weeks 4-6 and 1x/week during Weeks 7-12. Follow-up interviews are conducted 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.


Eligibility criteria: Inclusion criteria:

* age \> 18 years
* current DSM-IV diagnosis of cocaine dependence
* maintained on a stable dose of methadone for \>1 month
* willing to sign informed consent
* English speaking

Exclusion criteria:

* serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, or substantial suicide risk) on the basis of history or medical examination
* dementia (\<23 on the Mini Mental State Exam)
* in recovery from pathological gambling as determined by DSM-IV criteria

Primary outcomes:
measure: Drug use
timeFrame: baseline and each follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Farmington
country: United States
facility: University of Connecticut Health Center
state: Connecticut
Study officials:
affiliation: UConn Health
name: Nancy Petry, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02091622: Increasing the Number of Patients Receiving Information About Transition to End-of-life Care
Official title: Increasing the Number of Patients Receiving Information About Transition to End-of-life Care: the Effect of a Half-day Physician and Nurse Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palliative Care
Disclosure
Lead sponsor: Umeå University
Sponsor class: OTHER
First posted: 2014-03-19
Enrollment: 1431
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Introduction: Honest prognostication and information for patients are important parts of end-of-life care. This study examined whether an educational intervention could increase the proportion of patients who received information about the transition to end-of-life care (ITEOL).

Method: Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses. The proportion of patients who received ITEOL was measured with data from the Swedish Register of Palliative Care (SRPC). Patients were only included if they died an expected death and maintained their ability to express their will until days or hours before their death. Four hospitals and four municipalities were assigned controls, matched by hospital size, population, and proportion of patients receiving ITEOL at baseline.


Eligibility criteria: Inclusion Criteria:

* Hospitals and municipalities: Participation in the Swedish Register of Palliative Care.
* Patients: Reported from an included hospital or municipality during six months before to six months after intervention.

Exclusion Criteria:

* Hospitals and municipalities: Exclusion criteria were more than 40% patients receiving ITEOL at start of study, too large for an intervention due to practical reasons (university hospitals or municipalities with over 100 000 inhabitants), and hospitals not containing both internal medicine and surgery departments.
* Patients were excluded when death was unexpected, when a forensic post mortem examination was performed, or when the patients had lost their ability to express their will and take part in decisions concerning the content of medical care one week or more before death.

Primary outcomes:
measure: The proportion of patients who received ITEOL
timeFrame: Six months after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Umeå
country: Sweden
facility: Umeå University, Dept of radiation sciences
Study officials:
affiliation: Umeå University
name: Bertil Axelsson, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: